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Dystroglycan is a member of the transmembrane dystrophin glycoprotein complex in muscle that binds to the
synapse-organizing molecule agrin. Dystroglycan binding and AChR aggregation are mediated by two separate domains of
agrin. To test whether dystroglycan plays a role in receptor aggregation at the neuromuscular junction, we overexpressed
it by injecting rabbit dystroglycan RNA into one- or two-celled Xenopus embryos. We measured AChR aggregation in
myotomes by labeling them with rhodamine–a-bungarotoxin followed by confocal microscopy and image analysis.
ystroglycan overexpression decreased AChR aggregation at the neuromuscular junction. This result is consistent with
ystroglycan competition for agrin without signaling AChR aggregation. It also supports the hypothesis that dystroglycan
s not the myotube-associated specificity component (MASC), a putative coreceptor needed for agrin to activate
uscle-specific kinase (MuSK) and signal AChR aggregation. Dystroglycan was distributed along the surface of muscle
embranes, but was concentrated at the ends of myotomes, where AChRs normally aggregate at synapses. Overexpressed
ystroglycan altered AChR aggregation in a rostral–caudal gradient, consistent with the sequential development of
euromuscular synapses along the embryo. Increasing concentrations of dystroglycan RNA did not further decrease AChR
ggregation, but decreased embryo survival. Development often stopped during gastrulation, suggesting an essential,
onsynaptic role of dystroglycan during this early period of development. © 2000 Academic Press
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At the neuromuscular junction, acetylcholine receptors
(AChRs) aggregate opposite the motor nerve terminal at a
much higher concentration than in the rest of the muscle
cell membrane. The establishment of this asymmetric
distribution is directed by the extracellular matrix mole-
cule agrin. Agrin is a proteoglycan produced by motor
neurons that interacts with the muscle-specific kinase
(MuSK) receptor on the postsynaptic membrane to stimu-
late aggregation of AChRs. Before MuSK was identified,
several laboratories discovered that agrin binds to
1 Current address: Department of Pathology and Anatomy, East-
tern Virginia Medical School, Norfolk, VA 23501.
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All rights of reproduction in any form reserved.a-dystroglycan (Bowe et al., 1994; Campanelli et al., 1994;
Gee et al., 1994; Sugiyama et al., 1994). a-Dystroglycan is
part of the dystrophin glycoprotein complex in muscle
membrane that links the extracellular matrix to the cy-
toskeleton and whose disruption is associated with several
forms of muscular dystrophy (Campbell, 1995). Dystrogly-
can undergoes posttranslational cleavage to form a- and
b-dystroglycan. b-Dystroglycan is a transmembrane protein
hat binds to dystrophin on the cytoplasmic side of the
embrane and to a-dystroglycan on the extracellular side.
n addition to agrin, a-dystroglycan binds to laminin and
ossibly perlecan, all of which contain laminin G (LG)
omains (Hemler, 1999). a-Dystroglycan is not the agrin
eceptor inducing AChR aggregation, since elimination of
he dystroglycan-binding domain of agrin does not remove
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596 Heathcote et al.its AChR-aggregating activity (Gesemann et al., 1996; Hopf
and Hoch, 1996). A current hypothesis is that dystroglycan
is involved in the growth and/or maintenance of AChR
aggregates by a MuSK-independent mechanism (Montanaro
et al., 1998; Jacobson et al., 1998; Grady et al., 2000). To test
the role of dystroglycan in regulating AChR aggregation, we
overexpressed it in the developing Xenopus embryo during
synaptogenesis at the neuromuscular junction.
Overexpression of mammalian dystroglycan resulted in a
reduction of AChR aggregation during neuromuscular syn-
aptogenesis. This result, like those of knockdown or knock-
out experiments (Jacobson et al., 1998; Grady et al., 2000),
is not consistent with dystroglycan being a coreceptor for
agrin–MuSK signaling. The reduction of AChR aggregation
could most easily be explained by agrin binding to the
additional dystroglycan instead of MuSK. Since dystrogly-
can is present throughout the entire muscle membrane
during normal development, it could serve as an agrin sink,
to reduce AChR aggregation caused by agrin originating
from other cell types, including muscle (see Godfrey et al.,
1999). Thus the combination of MuSK stimulating AChR
aggregation at the site of nerve contact and dystroglycan
inhibiting AChR aggregation at other sites could focus
synaptic development to the region directly under the nerve
terminal.
MATERIALS AND METHODS
RNA Synthesis
Dystroglycan RNA for overexpression in Xenopus embryos was
ynthesized from a rabbit cDNA (Ibraghimov-Beskrovnaya et al.,
992). The dystroglycan cDNA was inserted into the pCS21
lasmid (Rupp et al., 1994; Turner and Weintraub, 1994) and used
s a template for RNA synthesis. In a similar manner, the cDNA
or a red-shifted form of green fluorescent protein (GFP) was
repared for the synthesis of GFP RNA. Plasmids were linearized
nd RNA was synthesized with an SP6 mMessage mMachine kit
Ambion, Austin, TX). Agarose gel electrophoresis showed the
roduct of each reaction as a single band whose concentration was
etermined by comparison with mass standards. RNAs were di-
uted for embryonic injection (0.5, 1.0, and 2.0 mg/ml for dystrogly-
an RNA; 0.1 mg/ml for GFP RNA; 2.0 and 3.0 mg/ml for agrin RNA;
see Godfrey et al., 1999).
Overexpression
RNA encoding dystroglycan and/or GFP was injected into early
embryos of the frog Xenopus laevis. Synchronized embryos from a
single female were obtained by artificial insemination (Moon and
Christian, 1989). Blastomeres were injected with RNAs at the one-
or two-cell stage with 4.5 nl from a Nanoject injector (Drummond
Scientific, Broomall, PA). Following injection, properly developing
embryos were selected at several stages. The first selection was for
animals that initiated cleavage. The next day, embryos that suc-
cessfully completed gastrulation were selected and screened for
GFP expression. GFP was generally expressed throughout large
contiguous regions (Godfrey et al., 1999), but only embryos with
GFP expression in myotomes 5, 6, and 7 were accepted for further
Copyright © 2000 by Academic Press. All rightanalysis. Following a final selection for normal development to the
tail bud stage (1.6 days; st 31), embryos were fixed and prepared for
microscopy.
Fixation and Staining
To assay the effect of dystroglycan overexpression on receptor
aggregation, AChRs were labeled at the tail bud stage of develop-
ment (1.6 days, st 31). Embryos were fixed in 4% paraformaldehyde
for 1 h at 4°C and washed in Ringers. Skin was removed and AChRs
were marked with rhodamine–a-bungarotoxin (1:500; Molecular
Probes, Eugene, OR) overnight at 4°C. Stained embryos were
mounted on slides for confocal microscopy.
Immunocytochemistry was used to determine the distribution
of dystroglycan in normal embryos and after overexpression. Fol-
lowing fixation, embryos were cryoprotected in sucrose, embedded
in TBS tissue freezing medium (Fisher, Pittsburgh, PA), and frozen.
Cryostat sections of embryos were placed on Superfrost Plus slides
(Fisher) and fixed again (2% paraformaldehyde for 15 min) to secure
sections to slides. Sections were incubated in blocking solution
(3% BSA in PBS, 1 h), and then primary antibody (1:100, 1 h), a
sheep polyclonal to FP-B: a fusion protein corresponding to the
cleavage point between a- and b-dystroglycan in rabbit
Ibraghimov-Beskrovnaya et al., 1992) that cross-reacts with
b-dystroglycan in Xenopus (Cohen et al., 1995). After washing,
FITC-labeled goat anti-sheep secondary antibody (1:200, 30 min;
Vector Laboratories, Burlingame, CA) was used to localize dystro-
glycan. After final washing, sections were mounted in 90% glycerol
with Vectashield (Vector Laboratories) and coverslipped for confo-
cal microscopy. In some cases rhodamine–a-bungarotoxin was
dded to label AChRs and dystroglycan in the same section.
Confocal Microscopy and Image Analysis
To examine synaptic AChR aggregation and dystroglycan distri-
bution, the ends of myotomes in whole-mount embryos or sections
were examined with a confocal microscope (Bio-Rad MRC 600). We
obtained stacks of confocal images from synaptic regions and
initially chose six representative regions from myotome 5, 6, or 7 in
a group of 10 identically treated sibling animals. In later experi-
ments, we analyzed synaptic regions of all three of these myotomes
from each of 6 animals.
To quantify data from image stacks, Metamorph (Universal
Imaging, West Chester, PA) and Image J (NIH, Bethesda, MD)
software was used. The threshold for AChR aggregate staining was
set and the percentage of the image area in the entire stack that
exceeded threshold was determined. This provides a measure of the
size and number of AChR aggregates within identical areas of the
embryonic muscle.
Statistics
To compare and analyze data, the Prism (Graphpad, San Diego,
CA) graphing and statistical software package was used. Analyses
included t tests, linear regression, and ANOVA.
RESULTS
Dystroglycan Localization
The distribution of dystroglycan in developing musclewas determined after the formation of functional synapses.
s of reproduction in any form reserved.
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Copyright © 2000 by Academic Press. All rightThe FP-B antibody (Ibraghimov-Beskrovnaya et al., 1992;
Cohen et al., 1995) was used to stain parasagittal frozen
sections of normal Xenopus embryos at 1.6 days (st 31; Fig.
1A). A projected stack of confocal images showed a broad
region of concentrated dystroglycan immunoreactivity at
the intermyotomal septum. Close inspection showed indi-
vidual muscle cells outlined with fluorescence, indicating
that dystroglycan was also expressed in muscle cell mem-
branes away from the intermyotomal septum. This stage is
approximately 12 h after the first sign of functional syn-
apses, namely reflexive movements of the embryo (Nieuw-
koop and Faber, 1994). The asymmetric distribution of
dystroglycan within muscle tissue was readily apparent
shortly after the formation of functional synapses.
Colocalization experiments showed the relationship be-
tween dystroglycan and AChR aggregates at developing
synapses. The projected stack of red images (rhodamine–a-
bungarotoxin) was layered on top of the green images and
showed the positions of AChR aggregates in the section
(Fig. 1A). Most AChR aggregates were also located at the
ends of myotomes, the sites of mature synapses; however,
the region of high dystroglycan concentration was more
extensive than the AChR aggregates. There were also AChR
aggregates outside the normal synaptic region, which are
shown as red areas surrounded by a thin ring of green
dystroglycan staining. The number of these “extrajunc-
tional” AChR aggregates decreased during development,
suggesting that the synaptic regions of muscle cell mem-
branes (where dystroglycan is concentrated) can better
maintain AChR aggregates. At this stage of development,
dystroglycan was colocalized with all AChR aggregates, but
aggregates did not form exclusively in regions of concen-
trated dystroglycan.
To test whether RNA injection resulted in overexpres-
sion of dystroglycan during neuromuscular synaptogenesis,
we used an antibody to probe for the additional protein.
the broad region of dystroglycan immunoreactivity. (B) A frozen
horizontal section of an embryo at 1.8 days (st 33/34) which had
one cell injected with dystroglycan RNA at the two-cell stage. A
stack of images has been projected. Dystroglycan expression in
several segments show much brighter staining on the right side,
indicating that dystroglycan protein was successfully overex-
pressed. Note that on both sides, the outer edge of the spinal cord
is stained. (C) Plot profile of equal rectangular areas from each side
of the spinal cord of the animal shown in B. The plot is from section
6 of seven in the confocal stack. The peaks correspond to the
regions of high intensity at the intermyotomal septum (synaptic
regions). The intensities of both the peaks and the background were
approximately doubled on the right (injected) side. For all seven
sections, the three control peak areas were 54% of the injected side
(P , 0.0001; paired t test) and the three control baseline areas were
48% of the injected side (P , 0.0001; paired t test). Even though
the differences were consistent and significant, there was variabil-
ity in the intensity on the injected side (between the second and theFIG. 1. Dystroglycan distribution. (A) A frozen sagittal section of
a normal embryo at 1.6 days (st 31). Dystroglycan is marked with
the FP-B antibody (green) and AChRs are marked with rhodamine-
labeled bungarotoxin (red). Stacks of confocal images for each color
have been projected and red is layered on top of the green. The
broad green region is the intermyotomal septum, where synapses
normally form. Less intense staining outlines the other surfaces ofthird peaks). Calibration: A, 20 mm; B, 100 mm.
s of reproduction in any form reserved.
b
a
f
fl
b
i
d
t
1
p
o
t
s
r
n
g
i
s
i
1
t
e
s
1
i
s
(
g
s
t
c
a
p
t
c
R
c
t
s
o
f
A
i
s
g
A
i
m
o
2
a
c
s
o
e
e
t
t
U
(
f
e
f
t
f
w
t
(
r
I
o
m
w
v
F
g
g
2
T
f
c
d
m
n
t
p
t
d
c
g
598 Heathcote et al.RNA encoding rabbit dystroglycan (Ibraghimov-
Beskrovnaya et al., 1992) was injected into fertilized em-
ryos and dystroglycan protein was localized with the FP-B
ntibody. Since FP-B recognizes both rabbit and endogenous
rog dystroglycan (Cohen et al., 1995), we compared the
uorescence in muscles of injected and uninjected em-
ryos. To minimize interanimal variability in staining, we
njected one cell at the two-cell stage with 2.3 ng of
ystroglycan RNA. In control experiments with GFP RNA,
his produced expression in half the embryo (Godfrey et al.,
999). If injection of dystroglycan RNA results in overex-
ression, there should be an increase in staining intensity
n one side of the animal. An image of a horizontal section
hrough such an animal shows the right side more intensely
tained than the left (Fig. 1B), indicating overexpression of
abbit dystroglycan. Muscle fibers on both sides appear
ormal and are similar in diameter, indicating that dystro-
lycan has not disrupted muscle development. In this
mage, the periodic horizontal lines that are more brightly
tained than the surrounding tissues correspond to the
ntermyotomal septa shown at higher magnification in Fig.
A. The differential staining appeared to be maintained on
he injected side. Quantitative analysis of equal areas from
ach side of the image confirmed that the intermyotomal
epta were always more intensely stained on both sides (Fig.
C). A typical analysis showed that the amount of staining
n peak and background areas from each section in this
tack was approximately doubled on the injected side
control peaks were 54% of injected peaks, control back-
round was 48% of injected background) and both were
ignificantly different from control (P , 0.0001; paired t
est). The quantification also showed that overexpression
an be variable. The background level between the second
nd the third peaks on the right side decreased and ap-
roached the level on the control side. This suggests that
he larger dystroglycan RNA may not diffuse to all of the
ells on the injected side as readily as the smaller GFP
NA. Additional staining between the myotome/spinal
ord border was greater than background, but not as great as
he intermyotomal septum. Thus the boundaries between
egments and between some tissue types appear to be sites
f dystroglycan accumulation. The embryo in Fig. 1B is
rom a later stage (1.8 days; st 33/34) than used for testing
ChR aggregation (see below). Thus, RNA injection results
n the elevation of dystroglycan protein levels, which per-
ist well past the initial stages of neuromuscular synapto-
enesis examined in these experiments.
Dystroglycan Reduces AChR Aggregation
Overexpression of dystroglycan did not qualitatively alter
AChR aggregation at developing neuromuscular junctions.
Following fertilization, animals were injected with a mix-
ture of dystroglycan and GFP RNAs (experimental) or with
GFP RNA (control). After translation into protein, the green
GFP fluorescence marked animals successfully injected
with RNA and synaptic regions appropriate for analysis.
Copyright © 2000 by Academic Press. All rightfter being labeled with rhodamine–a-bungarotoxin, the
ntermyotomal synaptic regions were analyzed by confocal
icroscopy. Projected stacks of images from control (GFP
nly, Fig. 2A) and experimental (dystroglycan and GFP, Fig.
B) synaptic regions showed similar localizations of AChR
ggregates. The prominent bright line across both images
orresponds to the boundary between myotomes where
ynapses normally form. There were also AChR aggregates
utside the normal synaptic regions at this stage in both
xperimental and control animals. To quantify the differ-
nces in AChR aggregation between experimental and con-
rol animals, we measured the fluorescent area throughout
he entire stack with image analysis software (Metamorph,
niversal Imaging). The AChR aggregate area in control
Fig. 2A) and experimental (Fig. 2B) images differed by a
actor of 2 (1.24 and 0.68% of the total area in control and
xperimental images, respectively). The only apparent dif-
erence between synaptic regions of experimental and con-
rol animals was the quantity of AChR aggregation.
To test whether the reduction in AChR aggregation
ollowing overexpression of dystroglycan was significant,
e quantitatively analyzed the synaptic regions of myo-
omes from several groups of animals. Synaptic regions
between myotomes 5/6, 6/7, and 7/8) were imaged, and six
epresentative regions were selected for analysis (Fig. 3A).
n the synaptic regions from experiment a, there was some
verlap of experimental and control values with the experi-
ental average at 62% of control. In experiment b, there
as less overlap with average experimental AChR aggregate
olume reduced to less than half (45%) of control (images in
ig. 2 come from experiment a). In 17 of 24 experimental
roups, dystroglycan overexpression decreased AChR aggre-
ation below control levels. The largest decrease was to
8.6% of control, with many reductions exceeding 50%.
he average change for all 24 experiments (calculated
ollowing logarithmic conversion) decreased to 76.1% of
ontrol. To test the significance of the decrease, the raw
ata from all of the synaptic regions receiving each treat-
ent were combined (Fig. 3B). Although this analysis does
ot take into account the variation between experiments or
he possible variation within an experiment due to incom-
lete diffusion of dystroglycan RNA (see Fig. 1C), it showed
hat AChR aggregation in experimental synaptic regions
ecreased significantly (P 5 0.005; t test) to 77.8% of
ontrol. Thus additional dystroglycan decreased AChR ag-
regation.
Dystroglycan Inhibits Development of AChR
Aggregation
Overexpression of dystroglycan could cause AChR aggre-
gation resembling that of synapses at earlier stages of
development. Somites form in a rostral–caudal gradient;
AChR aggregation on myotomal muscles derived from
them should develop in a similar manner. If a gradient in
AChR aggregation exists in normal animals, comparing it
with animals at the same stage overexpressing dystroglycan
s of reproduction in any form reserved.
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599Dystroglycan Inhibits Receptor Aggregationcould indicate whether the reduction of AChR aggregation
in experimental animals was slowed, stopped, or disrupted.
FIG. 2. Synaptic AChR distribution following overexpression. (A)
eceptor aggregates in muscles overexpressing GFP. Image from a
hole-mount embryo at 1.6 days (st 31) that was injected with GFP
NA at the one-cell stage. Projected stack of confocal images of a
ynaptic region stained with rhodamine–a-bungarotoxin. The AChR
ggregate area is 1.24% of the entire image stack. (B) Dystroglycan
verexpression. Image from a sibling injected with GFP and dystro-
lycan RNAs. The AChR aggregate area is reduced to 0.68%, approxi-
ately half that of the GFP control in A. Both images are from
yotome 5, have extrasynaptic AChR aggregates, and appear similar
xcept for the AChR aggregate area. Calibration: 20 mm.In addition, by examining differences between synaptic
Copyright © 2000 by Academic Press. All rightegions in the same animals, more powerful statistical
nalyses can be used.
To determine if a rostral–caudal gradient of AChR aggre-
ation occurs at neuromuscular synapses in control ani-
FIG. 3. Dystroglycan overexpression decreased AChR aggrega-
tion. (A) Raw AChR aggregation data. Each set of experiments came
from siblings: some injected with GFP RNA alone (control, GFP)
and others injected with a mixture of GFP and dystroglycan RNAs
(experimental, DG). Confocal image stacks from six synaptic
regions in each set were analyzed. The AChR aggregate area for
each synaptic region sampled in two different sets of experiments
is shown, as well as the average for each treatment. Variation
occurred within and between experiments. In experiment a, the
dystroglycan average was 62% of control (P 5 0.009; df 5 10; t
test) and in experiment b, it was 45% of control (P 5 0.003; df 5
10; t test). Figure 2 images come from experiment a. 17 of 24
experiments showed a decrease in AChR aggregation of DG versus
GFP. (B) The AChR aggregate area for all synaptic regions receiving
each treatment showed a significant (P 5 0.005; df 5 250; t test)
dystroglycan-associated decrease to 77.8% of control.
s of reproduction in any form reserved.
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600 Heathcote et al.mals, we obtained images from sequential segmental syn-
aptic regions. Images of synaptic regions between
myotomes 5 and 6 (Fig. 4A), 6 and 7 (Fig. 4B), and 7 and 8
(Fig. 4C) were obtained from an animal overexpressing only
GFP (control). There was a progressive decrease in the area
of rhodamine–a-bungarotoxin-stained AChR aggregates
long the rostral–caudal axis in this animal. Measurement
f AChR aggregation (Fig. 4E, inset) provides a quantitative
onfirmation of the result. Although this trend was appar-
nt in many animals, there were exceptions. When data
rom all control (GFP) animals were combined (Fig. 5), the
rogressive reduction in AChR aggregation along the
ostral–caudal axis was apparent. The synaptic region be-
ween myotomes 7 and 8 (“myotome 7”) had 70% of the
FIG. 4. Rostral–caudal gradient of AChR expression. Top: Image
(control). Projected confocal stacks from somites 5 (A), 6 (B), and
decreased to 1.59% at somite 6 and 1.12% at somite 7. Bottom: Si
RNAs (experimental). Images are from somites 5 (D), 6 (E), and 7 (F
inset in E plots the quantitative amounts for each image. Both contr
aggregation. Calibration: 20 mm.verage AChR aggregate volume present in the region a
Copyright © 2000 by Academic Press. All rightetween myotomes 5 and 6 (“myotome 5”). The overall
ifference across segments was highly significant (P ,
.001; repeated-measures ANOVA) for control synaptic
egions. Thus there was a distinct gradient in AChR aggre-
ation along the rostral–caudal axis.
To test the patterns of AChR aggregation following
verexpression of dystroglycan, we obtained similar images
rom experimental animals. The three synaptic regions
orresponding to the control (Figs. 4A–4C) are shown for a
ibling animal (Figs. 4D–4F) receiving experimental treat-
ent (dystroglycan plus GFP RNAs). As in the control,
here was a progressive quantitative decrease in AChR
ggregation along the rostral–caudal axis of this animal (Fig.
E, inset). Combining data from all experimental (DG)
a whole-mount embryo (1.6 day, st 31) injected with GFP RNA
. The greatest AChR aggregation area was at somite 5 (1.82%); it
series from a sibling embryo injected with GFP and dystroglycan
respective AChR aggregate areas were 1.14, 0.89, and 0.42%. The
d experimental animals showed a rostral–caudal gradient of AChRs from
7 (C)
milar
). The
ol annimals (Fig. 5) shows a progressive reduction in AChR
s of reproduction in any form reserved.
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601Dystroglycan Inhibits Receptor Aggregationaggregation along the rostral–caudal axis. The magnitude of
the decrease was 70% between myotomes 5 and 7.
Repeated-measures ANOVA showed a highly significant
overall difference (P , 0.001; t test) between AChR
aggregation in these synaptic regions. As with controls,
there was a gradient along the rostral–caudal axis.
Similar rostral–caudal gradients in control and experi-
mental animals would suggest that dystroglycan inhibits or
slows development. Since the morphological structures
characteristic of developmental stage were the same and
muscle fiber sizes were similar (diameters are approxi-
mately 10 mm) in experimental and control animals, excess
ystroglycan had a differential effect on AChR aggregation.
he rostral–caudal data for experimental and control
roups showed similar trends, but experimental values for
ach somite decreased to approximately 70% of control
Fig. 5). These differences were reduced from experiments
hat did not distinguish between different axial levels (Fig.
FIG. 5. Dystroglycan inhibits AChR aggregation along a rostral–
caudal gradient. Average AChR aggregation volume (with SEM) for
all synaptic regions at each myotome border is shown. All three
myotomes were analyzed in control (GFP; n 5 54) and experimen-
tal (DG; n 5 86) animals. A gradient is evident with the greatest
and least AChR aggregation in the most rostral (5) and caudal (7)
myotomes, respectively. Repeated-measures ANOVA showed sig-
nificant overall differences between AChR aggregation areas across
the three myotomes in both GFP and DG animals (P , 0.001 for
ach). Of all combinations within each group, only the synaptic
egions between myotomes 5 and 6 in GFP-treated animals were
ot significantly different (P 5 0.08; compared using an unpaired
t test). Regression analysis of the data for each experimental group
showed similar slopes (20.12 for GFP and 20.09 for DG). The
roughly parallel lines suggest that the experimental treatment
inhibited AChR aggregation by a constant amount at each segment.
The experimental (DG) value at myotome 5 is similar to the
control (GFP) value at myotome 7, indicating that development in
experimental animals lagged two segments behind controls.C) and were significant at each somite (P , 0.05). s
Copyright © 2000 by Academic Press. All rightRegression analysis showed a linear trend in AChR aggre-
gate volume among the segments at the three synaptic
regions (Fig. 5). Both control (GFP) and experimental (DG)
groups have similar slopes (20.12 for GFP and 20.09 for
DG), confirming their parallel appearance. In animals over-
expressing dystroglycan, the synaptic region of myotome 5
had roughly the same amount of AChR aggregation as
synaptic regions at myotome 7 in controls. The similar
slopes of AChR aggregation along the rostral–caudal axis
(Fig. 5) suggest that experimental synaptic regions are two
somites behind controls in their development. Thus dystro-
glycan apparently retarded the aggregation of AChRs and
presumably the function of these developing synapses.
Developmental Effects of Dystroglycan
Overexpression
Dystroglycan appeared to reduce AChR aggregation in a
constant and linear fashion; it also appeared to disrupt
development at earlier stages. Fertility and successful de-
velopment varied for each batch of eggs. To determine
whether dystroglycan affected embryogenesis, we measured
the survival of over 15,000 animals from 16 groups that
received three different treatments: (1) injection with dys-
troglycan and GFP, (2) injection with GFP, and (3) no
injection. The percentage of uninjected controls that started
cleaving and successfully reached the tail bud stage (st 31)
was twice that of either injected group of siblings (Fig. 6A).
Injection of both dystroglycan and GFP RNA resulted in
significantly lower survival than in uninjected controls
(P , 0.001; t test), but they did not differ from each other,
suggesting that RNA injection affected embryo survival.
However, embryos injected with dystroglycan RNA fre-
quently showed developmental defects that were associated
with gastrulation (Fig. 7). Multiple sites of gastrulation,
incomplete gastrulation, and exogastrulation were among
the defects found in embryos that did not survive.
To determine whether dystroglycan affected gastrulation,
we injected different amounts of dystroglycan RNA and
measured embryo survival. To eliminate potential variabil-
ity between RNA preparations, we serially diluted the RNA
from a single preparation and injected 2.3 ([DG]), 4.6
(2[DG]), and 9.2 (4[DG]) ng into each embryo. Only the
largest amount of dystroglycan RNA (4[DG]) decreased
survival below that of control (GFP) embryos (Fig. 6B). It is
unlikely that the reduction in survival was due to the
greater quantity of exogenous RNA, since equal and greater
amounts of the similar-sized RNA encoding the carboxyl-
terminal portion of agrin 0,0 (Godfrey et al., 1999) RNA
4[AG] or 9.2 ng and 6[AG] or 13.8 ng) did not have this
ffect (Fig. 6B). Surprisingly, we did not detect a dose-
ependent decrease in AChR aggregation in response to
igher amounts of dystroglycan RNA (data not shown).
We measured viability at three embryonic stages to
etermine if gastrulation was specifically affected. First, we
easured the percentage of embryos that successfullytarted cleaving (Fig. 6C). Since embryos injected with GFP
s of reproduction in any form reserved.
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Copyright © 2000 by Academic Press. All rightor the lowest concentration of dystroglycan had a survival
frequency similar to that of those injected with the inter-
mediate concentration of dystroglycan RNA, only the
2[DG] is shown. Survival was less than that of controls, but
neither concentration of dystroglycan prevented embryos
from starting to cleave. Those surviving to the next day
FIG. 7. Developmental defects following overexpression of dys-
troglycan. Embryos injected with dystroglycan showed decreased
survival between cleavage and neurulation. Many of the animals
showed defects in gastrulation, including multiple sites of gastru-
lation, incomplete gastrulation, and exogastrulation. A number of
defective embryos injected with dystroglycan RNA are shown next
to a single normal sibling (top) that gastrulated and underwent
successful neurulation. Calibration: 1 mm.
FIG. 6. Dystroglycan overexpression affects embryonic survival.
(A) RNA injection decreased the survival of cleaving embryos to
tail bud stage. Data are from more than 15,000 embryos produced
by 16 females. Repeated-measures ANOVA shows that survival
was significantly different across the three groups (P , 0.001). The
Newman–Keuls posttest showed that the survival of animals
injected with GFP RNA or a mixture of dystroglycan and GFP
RNAs was significantly decreased from that of uninjected controls
(P , 0.001) but not from each other. (B) Survival from cleavage to
tail bud was examined for animals injected with different concen-
trations of dystroglycan (n 5 492 (Control), 661 (GFP; 0.5 ng), 690
[DG]; 2.3 ng), 596 (2[DG]; 4.6 ng), 666 (4[DG]; 9.2 ng), 473 (4[AG];
.2 ng), 157 (6[AG]; 13.8 ng). Animals receiving the greatest amount
f dystroglycan RNA (4[DG] or 9.2 ng) showed decreased survival
ut this was not evident in animals injected with equal or greater
mounts of agrin RNA (4[AG] or 9.2 ng and 6[AG] or 13.8 ng) in
ther experiments. (C) To determine when additional dystroglycan
isrupts embryogenesis, survival was analyzed at several stages.
ince the effects of GFP and [DG] were similar to those of 2[DG]
NA, only the latter is shown. The largest quantities of DG RNA
ecreased survival the greatest during gastrulation.s of reproduction in any form reserved.
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603Dystroglycan Inhibits Receptor Aggregationwere in the middle of neurulation, but most injected with
the highest concentration of dystroglycan RNA did not
survive (Fig. 6C). These embryos had multiple sites of
gastrulation, incomplete gastrulation, and exogastrulation
(Fig. 7) and were unable to continue normal development.
Those that successfully completed gastrulation had a better
chance of surviving to the tail bud stage (Fig. 6C). Thus,
overexpression of high concentrations of dystroglycan de-
creased survival during gastrulation.
DISCUSSION
The Developmental Role of Dystroglycan
Dystroglycan is part of the dystrophin glycoprotein com-
plex in muscle cells. Two dystroglycan proteins are pro-
duced from a polypeptide that is posttranslationally modi-
fied. Dystroglycan apparently plays a critical role in early
development, since knockout mice are unable to form
basement membranes and stop developing early in embryo-
genesis (Williamson et al., 1997; Henry and Campbell,
1998). In Duchenne muscular dystrophy, dystrophin is
missing and dystroglycan is dramatically reduced (Ervasti et
al., 1990), thereby eliminating the link between the cy-
toskeleton and the extracellular matrix. Presumably, the
proper localization of dystroglycan is important for muscle
integrity (Durbeej et al., 1998a).
The role of dystroglycan during early development may
be related to its function in forming basement membranes,
a component of extracellular matrix. Mice lacking dystro-
glycan are unable to make Reichert’s membrane and stop
developing quite early (Williamson et al., 1997). Electron
microscopy showed that embryonic stem cells missing the
dystroglycan gene make structures that lack basement
membranes, but transfection with functional dystroglycan
cDNA restores their ability to do so (Henry and Campbell,
1998). Our experiments increased dystroglycan expression
and often resulted in defective gastrulation. Thus, too little
or too much dystroglycan can disrupt early development.
Although we did not examine basement membranes, gas-
trulation marks the start of extensive cell movements in
the amphibian embryo, which are dependent upon cell
attachment to extracellular matrix molecules. An inappro-
priate linkage between the cytoskeleton and the extracel-
lular matrix could disrupt cell migration during gastrula-
tion. Dystroglycan links the cytoskeleton to the
extracellular matrix in differentiated muscle cells and may
have a similar function early in development.
There is an asymmetric distribution of dystroglycan
during normal development. Many epithelial cell types
express dystroglycan on their basal side during differentia-
tion (Durbeej et al., 1995) and as mature cells (Durbeej et
l., 1998b). The embryonic brain and spinal cord express
ystroglycan RNA (Schofield et al., 1995), which could
ccount for the immunoreactivity on the basal surface of
he neural tube. In skeletal muscle, dystroglycan is present
n the sarcolemmal membrane and is concentrated at the
Copyright © 2000 by Academic Press. All righteuromuscular and myotendinous junctions (see Durbeej et
l., 1998b). In embryonic Xenopus myotomes, neuromus-
ular junctions are located at the intermyotomal septum,
hich is homologous to the myotendinous junction in
dults (Cary and Klymkowsky, 1995). The enrichment of
ystroglycan immunoreactivity at the ends of myotomes is
ikely due to the coincidence of neuromuscular and myo-
endinous junctions in Xenopus embryos. This asymmetry
as not evident in cultured myotomal muscle cells (Cohen
t al., 1995), perhaps because myotendinous junctions do
ot form in culture (Cary and Klymkowsky, 1995) and
euromuscular junctions differentiate over several days
ollowing nerve–muscle contact (Kullberg et al., 1977). The
nrichment of dystroglycan at normal neuromuscular junc-
ions may contribute to the extensive basal lamina associ-
ted with junctional folds at the synapse.
A Potential Role for Dystroglycan
at the Developing Synapse
The binding of a-dystroglycan to agrin has stimulated
nterest in a potential role for dystroglycan at the develop-
ng synapse. The agrin hypothesis (McMahan, 1990) states
hat postsynaptic differentiation of the neuromuscular
unction is induced by agrin, a protein secreted by the motor
erve terminal. The discovery that dystroglycan bound
grin (Bowe et al., 1994; Campanelli et al., 1994; Gee et al.,
994; Sugiyama et al., 1994) suggested that dystroglycan
ight be the agrin receptor. However, agrin fragments
hich no longer bound dystroglycan caused AChR aggrega-
ion (Gesemann et al., 1996; Hopf and Hoch, 1996). Agrin
ignaling is likely mediated by a complex of MuSK (DeChi-
ra et al., 1996) and a myotube-associated specificity com-
onent (MASC; Glass et al., 1996). Dystroglycan could
ediate AChR aggregation via a MuSK-independent path-
ay (Montanaro et al., 1998) that involves interactions
ith laminin (Sugiyama et al., 1997). Cells with reduced
evels or no a-dystroglycan showed reduced AChR aggrega-
ion in response to laminin and agrin, suggesting that
a-dystroglycan could contribute to the growth and/or sta-
bilization of AChR aggregates (Montanaro et al., 1998;
acobson et al., 1998; Grady et al., 2000). A reasonable
ypothesis based on this work is that dystroglycan overex-
ression should increase AChR aggregation by the MuSK-
ndependent pathway, yet our experiments show a decrease
n AChR aggregation. One possible explanation is that
xcess dystroglycan in vivo overcame stimulation of the
uSK-independent pathway and inhibited synaptic AChR
ggregation. Inhibition of AChR aggregation by dystrogly-
an supports the conclusion of Jacobson et al. (1998)
hat dystroglycan is not the MASC component of MuSK
ignaling.
How could dystroglycan decrease AChR aggregation?
ince a-dystroglycan binds to agrin strongly, it could act as
a competitive inhibitor of agrin by preventing interaction
with the MuSK/MASC complex. This would increase the
agrin threshold. Another possibility is that excess
s of reproduction in any form reserved.
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604 Heathcote et al.b-dystroglycan could bind to utrophin and inhibit cytoskel-
etal binding of AChRs. Dystroglycan associates with rapsyn
(Apel et al., 1995; Cartaud et al., 1998) and utrophin, a
dystrophin-like protein concentrated at the synapse (James
et al., 1996). b-Dystroglycan is part of a complex formed by
AChR with utrophin, rapsyn, and various synaptic kinases,
but it is not needed to maintain the complex (Fuhrer et al.,
1999). Thus we favor the idea that dystroglycan inhibits
agrin through a-dystroglycan rather than the AChR recep-
tor complex through b-dystroglycan. This provides a simple
xplanation for the parallel reduction of AChR aggregation
t neighboring myotomes in experimental and control ani-
als. Agrin binds to excess dystroglycan, so it cannot bind
o MuSK and induce AChR aggregation. This would occur
n both experimental and control animals, but additional
ystroglycan would retard AChR aggregation.
What is a potential role of dystroglycan in muscle cell
evelopment? It is unlikely that excess dystroglycan is
roduced during normal development, but its ability to
ecrease AChR aggregation in our experiments could reflect
biologically relevant phenomenon. A muscle isoform of
grin increases AChR aggregation when overexpressed in
ivo (Godfrey et al., 1999). Dystroglycan could act as a
uffer to inhibit ectopic aggregation caused by muscle
grin. At the site of nerve contact, focal release of agrin
ould eventually overcome the inhibition of dystroglycan.
he higher concentration of dystroglycan at the synaptic
egion would ensure that only the membrane directly
pposite an active nerve terminal would contain AChR
ggregates. Recent work suggests a potentially complemen-
ary function of dystroglycan in the formation of basement
embranes by interaction with laminin to assist in depos-
ting other basement membrane proteins (Williamson et al.,
997; Henry and Campbell, 1998) such as perlecan and
cetylcholinesterase (Peng et al., 1999). Muscle cells are
urrounded by basement membranes, including the special-
zation at the neuromuscular junction. Muscle isoforms of
grin, like laminin, could interact with dystroglycan around
he entire muscle cell to promote formation of its basement
embrane. Dystroglycan could interact with proteins con-
aining LG domains (laminin, agrin isoforms, perlecan;
eng et al., 1998) to form basement membranes around
uscle cells. At the neuromuscular junction, the additional
grin from nerve terminals would saturate dystroglycan
efore recruiting the receptors that effect AChR aggrega-
ion.
During development of the myotomal neuromuscular
ystem of Xenopus, there is a distinct rostral–caudal se-
uence in AChR aggregation. Somites in Xenopus form in a
ostral–caudal sequence (Nieuwkoop and Faber, 1994).
hus, caudal myotomes could express fewer AChRs and/or
audal motor neurons could express less agrin to direct
ChR aggregation. In either case, myotomal cells could
eceive synapses on opposite ends, which would recruit
ChRs produced by the single muscle nucleus. In higher
ertebrates, muscle cells receive and maintain a genetic tag
haracteristic of their rostral–caudal position in the embryo
Copyright © 2000 by Academic Press. All rightDonoghue et al., 1991). Although the differences in rostral–
audal timing of development are not as obvious in lower
ertebrates, they result in significant differences in AChR
ggregation at synapses of neighboring segments. These
ifferences could have functional consequences by affecting
mbryonic movements prior to hatching.
ACKNOWLEDGMENTS
We thank Jeremy Roe for assistance and John Buntin for advice.
This work was supported by NIH Grant MH-57545, NIEHS Center
Grant ES-04184, and the University of Wisconsin–Milwaukee.
K.P.C. is an investigator of the HHMI.
REFERENCES
Apel, E. D., Roberds, S. L., Campbell, K. P., and Merlie, J. P. (1995).
Rapsyn may function as a link between the acetylcholine recep-
tor and the agrin-binding dystrophin-associated glycoprotein
complex. Neuron 15, 115–126.
Bowe, M. A., Deyst, K. A., Leszyk, J. D., and Fallon, J. R. (1994).
Identification and purification of an agrin receptor from Torpedo
postsynaptic membranes: A heteromeric complex related to the
dystroglycans. Neuron 12, 1173–1180.
Campanelli, J. T., Roberds, S. L., Campbell, K. P., and Scheller,
R. H. (1994). A role for dystrophin-associated glycoproteins and
utrophin in agrin-induced AChR clustering. Cell 77, 663–674.
Campbell, K. P. (1995). Three muscular dystrophies: Loss of
cytoskeleton–extracellular matrix linkage. Cell 80, 675–679.
Cartaud, A., Coutant, S., Petrucci, T. C., and Cartaud, J. (1998).
Evidence for in situ and in vitro association between
b-dystroglycan and the subsynaptic 43K rapsyn protein. Conse-
quence for acetylcholine receptor clustering at the synapse.
J. Biol. Chem. 273, 11321–11326.
Cary, R. B., and Klymkowsky, M. W. (1995). Disruption of inter-
mediate filament organization leads to structural defects at the
intersomite junction in Xenopus myotomal muscle. Develop-
ment 121, 1041–1052.
Cohen, M. W., Jacobson, C., Godfrey, E. W., Campbell, K. P., and
Carbonetto, S. (1995). Distribution of a-dystroglycan during
embryonic nerve–muscle synaptogenesis. J. Cell Biol. 129, 1093–
1101.
eChiara, T. M., Bowen, D. C., Valenzuela, D. M., Simmons,
M. V., Poueymirou, W. T., Thomas, S., Kinetz, E., Compton,
D. L., Rojas, E., Park, J. S., Smith, C., DiStefano, P. S., Glass, D. J.,
Burden, S. J., and Yancopoulos, G. D. (1996). The receptor
tyrosine kinase MuSK is required for neuromuscular junction
formation in vivo. Cell 85, 501–512.
onoghue, M. J., Morris-Valerom R., Johnson, Y. R., Merlie, J. P.,
and Sanes, J. R. (1991). Mammalian muscle cells bear a cell-
autonomous, heritable memory of their rostrocaudal position.
Cell 69, 67–77.
Durbeej, M., Larsson, E., Ibraghimov-Beskrovnaya, O., Roberds,
S. L., Campbell, K. P., and Ekblom, P. (1995). Non-muscle
a-dystroglycan is involved in epithelial development. J. Cell Biol.
130, 79–91.
Durbeej, M., Henry, M. D., and Campbell, K. P. (1998a). Dystro-
glycan in development and disease. Curr. Opin. Cell Biol. 10,
594–601.
s of reproduction in any form reserved.
EJ
K
M
M
605Dystroglycan Inhibits Receptor AggregationDurbeej, M., Henry, M. D., Ferletta, M., Campbell, K. P., and
Ekblom, P. (1998b). Distribution of dystroglycan in normal adult
mouse tissues. J. Histochem. Cytochem. 46, 449–457.
rvasti, J. M., Ohlendieck, K., Kahl, S. D., Gaver, M. G., and
Campbell, K. P. (1990). Deficiency of a glycoprotein component
of the dystrophin complex in dystrophic muscle. Nature 345,
315–319.
Fuhrer, C., Gautam, M., Sugiyama, J. E., and Hall, Z. W. (1999).
Roles of rapsyn and agrin in interaction of postsynaptic proteins
with acetylcholine receptors. J. Neurosci. 19, 6405–6416.
Gee, S. H., Montanaro, F., Lindenbaum, M. H., and Carbonetto, S.
(1994). Dystroglycan-a, a dystrophin-associated glycoprotein, is a
functional agrin receptor. Cell 77, 675–686.
Gesemann, M., Cavalli, V., Denzer, A. J., Brancaccio, A., Schuma-
cher, B., and Ruegg, M. A. (1996). Alternative splicing of agrin
alters its binding to heparin, dystroglycan, and the putative agrin
receptor. Neuron 16, 755–767.
Glass, D. J., Bowen, D. C., Stitt, T. N., Radziejewski, C., Bruno, J.,
Ryan, T. E., Gies, D. R., Shah, S., Mattsson, K., Burden, S. J.,
DiStefano, P. S., Valenzuela, D. M., DeChiara, T. M., and
Yancopoulos, G. D. (1996). Agrin acts via a MuSK receptor
complex. Cell 85, 513–523.
Godfrey, E. W., Roe, J., and Heathcote, R. D. (1999). Overexpression
of agrin isoforms in Xenopus embryos alters the distribution of
synaptic acetylcholine receptors during development of the neu-
romuscular junction. Dev. Biol. 205, 22–32.
Grady, R. M., Zhou, H., Cunningham, J. M., Henry, M. D.,
Campbell, K. P., and Sanes, J. R. (2000). Maturation and mainte-
nance of the neuromuscular synapse: Genetic evidence for roles
of the dystrophin–glycoprotein complex. Neuron 25, 279–293.
Hemler, M. E. (1999). Dystroglycan versatility. Cell 97, 543–546.
Henry, M. D., and Campbell, K. P. (1998). A role for dystroglycan in
basement membrane assembly. Cell 95, 859–870.
Hopf, C., and Hoch, W. (1996). Agrin-binding to a-dystroglycan.
Domains of agrin necessary to induce acetylcholine receptor
clustering are overlapping but not identical to the
a-dystroglycan-binding region. J. Biol. Chem. 271, 5231–5236.
Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaugh-
ter, C. A., Sernett, S. W., and Campbell, K. P. (1992). Primary
structure of dystrophin-associated glycoproteins linking dystro-
phin to the extracellular matrix. Nature 355, 696–702.
Jacobson, C., Montanaro, F., Lindenbaum, M., Carbonetto, S., and
Ferns, M. (1998). a-Dystroglycan functions in acetylcholine
receptor aggregation but is not a coreceptor for agrin-MuSK
signaling. J. Neurosci. 18, 6340–6348.
ames, M., Man, N.-t., Wise, C. J., Jones, G. E., and Morris, G. E.
(1996). Utrophin–dystrophin complex in membranes of adherent
cultured cells. Cell Motil. Cytoskeleton 33, 163–174.
Copyright © 2000 by Academic Press. All rightullberg, R. W., Lentz, T. L., and Cohen, M. W. (1977). Develop-
ment of the myotomal neuromuscular junction in Xenopus
laevis: An electrophysiological and fine-structural study. Dev.
Biol. 60, 101–129.
cMahan, U. J. (1990). The agrin hypothesis. Cold Spring Harbor
Symp. Quant. Biol. 55, 407–418.
ontanaro, F., Gee, S. H., Jacobson, C., Lindenbaum, M. H.,
Froehner, S. C., and Carbonetto, S. (1998). Laminin and
a-dystroglycan mediate acetylcholine receptor aggregation via a
MuSK-independent pathway. J. Neurosci. 18, 1250–1260.
Moon, R. T., and Christian, J. L. (1989). Microinjection and expres-
sion of synthetic mRNAs in Xenopus embryos. Technique 1,
76–89.
Nieuwkoop, P. D., and Faber, J. (1994). “Normal Table of Xenopus
laevis (Daudin).” Garland, New York.
Peng, H. B., Afshan Ali, A., Daggett, D. F., Rauvala, H., Hassell,
J. R., and Smalheiser, N. R. (1998). The relationship between
perlecan and dystroglycan and its implication in the formation of
the neuromuscular junction. Cell Adhes. Commun. 5, 475–489.
Peng, H. B., Xie, H., Rossi, S. G., and Rotundo, R. L. (1999).
Acetylcholinesterase clustering at the neuromuscular junction
involves perlecan and dystroglycan. J. Cell Biol. 145, 911–921.
Rupp, R. A. W., Sinder, L., and Weintraub, H. (1994). Xenopus
embryos regulate the nuclear localization of XmyoD. Genes Dev.
8, 1311–1323.
Schofield, J. N., Gorecki, D. C., Blake, D. J., Davies, K., and
Edwards, Y. H. (1995). Dystroglycan mRNA expression during
normal and mdx mouse embryogenesis: A comparison with
utrophin and the apo-dystrophins. Dev. Dyn. 204, 178–185.
Sugiyama, J., Bowen, D. C., and Hall, Z. W. (1994). Dystroglycan
binds nerve and muscle agrin. Neuron 13, 103–115.
Sugiyama, J. E., Glass, D. J., Yancopoulos, G. D., and Hall, Z. W.
(1997). Laminin-induced acetylcholine receptor clustering: An
alternative pathway. J. Cell Biol. 139, 181–191.
Turner, D. L., and Weintraub, H. (1994). Expression of achaete-
scute homolog 3 in Xenopus embryos converts ectodermal cells
to a neural fate. Genes Dev. 8, 1434–1447.
Williamson, R. A., Henry, M. D., Daniels, K. J., Hrstka, R. F., Lee,
J. C., Sunada, Y., Ibraghimov-Beskrovnaya, O., and Campbell,
K. P. (1997). Dystroglycan is essential for early embryonic
development: Disruption of Reichert’s membrane in Dag1-null
mice. Hum. Mol. Genet. 6, 831–841.
Received for publication May 4, 2000
Revised August 10, 2000
Accepted August 10, 2000
Published online October 17, 2000
s of reproduction in any form reserved.
